Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy
Completed
Bayer
Phase 4
1993-03-01
The aim of the study was to compare the renoprotective effect of a long acting calcium
antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type
1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to
treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and
urinary excretion of albumin were measured every 6 months
Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy
Completed
Steno Diabetes Center
Phase 4
1993-03-01
The aim of the study was to compare the renoprotective effect of a long acting calcium
antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type
1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to
treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and
urinary excretion of albumin were measured every 6 months
Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy
Completed
Steno Diabetes Center Copenhagen
Phase 4
1993-03-01
The aim of the study was to compare the renoprotective effect of a long acting calcium
antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type
1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to
treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and
urinary excretion of albumin were measured every 6 months
Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets 40 mg
Completed
Mylan Pharmaceuticals
Phase 1
2007-02-01
The objective of this study was to investigate the bioequivalence of nisoldipine
extended-release 40 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release
40 mg tablet (manufactured for First Horizon) following a single, oral 40 mg (1 × 40 mg
tablet) dose administration in healthy adult subjects under fasting conditions.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
